Harrow, Inc. · NASDAQ:HROW
Harrow — Harrow Health — Investor Presentation (May 2023)
16 slides from Harrow's investor presentation, May 11, 2023
Slide 1: Harrow Corporate Presentation
HARROW Your patients. Our purpose. Corporate Presentation
Slide 2: Safe Harbor
Safe Harbor ‘his presentation contains express “forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995, You ore cautioned not fo rely on these forwarc:looking statements These statements are based on curten! expectations of future events. If derlying assu
Slide 3: Harrow (Nasdaq: HROW) Key Value Drivers
Harrow (Nasdaq: HROW) Key Value Driver o Ophthalmic pharmaceutical company serving 10,000* U.S. customers (doctors, hospitals, and ASCs) in the surgical, acute, and chronic care U.S. eyecare markets with branded pharmaceutical products (BPPs) and cGMP compounded pharmaceutical products (CPPs) © Oper
Slide 4: Harrow's Eyecare Pharmaceuticals Platform
Harrow’s Eyecare Pharmaceuticals Platform Highly-trusted, fully integrated pharmaceutical and pharmacy Platform consisting of national sales and customer service teams, large-scale automated cGMP drug compounding facili s, and an efficient, scalable, and tech- enabled national distribution platform
Slide 5: IHEEZO Launched at ASCRS in May 2023
IHEEZO™ Launched at ASCRS in May 2023 THEEZO (chloroprocaine HCI ophthalmic gel) 3% — Sterile, single-patient-use, physician-administered, ° Hale da et Saud eget market of ophthalmic gel preparation for ocular surface nee y — anesthesia, approved by FDA in September 2022. © First branded ocular anes
Slide 6: CPP Product Launches in 2023
CPP Product Launches.in 2023 © Forlisite is a patent-pending, refrigeration-stable, © Harrow has developed a patent-pending seties of compounded high-concentration ophthalmic compounded atropine formulations available through formulation of Tobramycin 1.5% + Vancomycin 5%. Harrow’s atropine.com bran
Slide 7: Fab Five Products and Strategy
Fab Five Products and Strategy
Slide 8: Landmark Branded Product Acquisition
Landmark Branded Product Acquisition With the January 2023 closing of the Fab Five transaction, Harrow began receiving net profits from all five products, pending the transfer of their New Drug Application (NDA). o NDAs were transferred for ILEVRO®, NEVANAC® and MAXIDEX® in late April 2023; and NDA
Slide 9: Fab Five Revitalization Strategy
Fab Five Revitalization Strategy To reverse recent revenue declines and build momentum towards the recovery of the economic potential of these assets, we plan to: According to IQVIA, within the last five © Actively manage the supply chain, ensuring adequate supply (>9 months years, aggregate annual
Slide 10: Used in ophthalmic markets where Harrow already has a foothold
Used in ophthalmic markels where Harrow already has a foothold, including 4.5 million cataract surgeries and 250K-400K vitrectomies( annually. The Fab Five Products gives our sales team a new call point - prescribers and institutions that will only purchase FDA- approved products - expanding our cus
Slide 11: Harrow U.S. Ophthalmic Portfolio
Harrow U.S./OphiiGlmic Portfolio Compounded Proprietary compounded product lines, not FDA approved; Cash pay, custom Rx needed Branded esaaietieneeicimiarientstea e Strategic Brands FDA-approv with gi ILEVRO.. DROP. LESS . GO Tess DR@PS THEEZO an reggie pita z | . @ siMpie LE SraRAE TEARS Nevanac VI
Slide 12: Equity Holdings and Royalty Pipeline
Equity Holdings and Royalty Pipeline
Slide 13: Potential "Hidden" Value
Potential “Hidden” Value Surface Ophthalmics, Melt Pharmaceuticals, and Eton Pharmaceuticals (Nasdaq: ETON), founded as Harrow subsidiaries, were carved-out after hiring management and closing external financings. Harrow owns: o 2million shares of Eton and equity in Surface and Melt (20% and 46%, re
Slide 14: Harrow Revenues and Core Gross Margin
Harrow Revenues and Core Gross Margin a (Revenues and Assets in Thousands) 75% $88,595 73% _ $51,165 sag.71 $41,372 $26,774 $26,103 $19,942 2014 2015 2016 2017 2018 2019 2020 2021 2022 1Q22 1Q23 lll Consolidated Revenues lll Core Gross Margin‘) (1) Core g1038 marginis c non-GAAP measure hat excludes
Slide 15: Summary of Harrow
Summary of Harrow (NASDAQ: HROW) Transformative acquisition oy Poised to achieve our vision 2023 expectations: /) expected to be immediately =) in} of becoming a leading Growing revenues, stable accretive to most 2023 top-tier U.S. eyecare core gross margins and financial metrics. pharmaceutical com
Slide 16: Harrow – Your patients. Our purpose.
(a HARROW Your patients. Our purpose. 102 Woodmont Blvd., Suite 610 Nashville, Tennessee 37205 www.Harrow.com Jamie Webb Director of Communications and Investor Relations jwebb@harrowinc.com Direct: 615-733-4737